Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6Neoplasms 3Lung Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pleural Effusion 1Pituitary Diseases 1Pituitary ACTH Hypersecretion 1Obesity 1Myasthenia Gravis 1Motor Activity 1Lymphoma 1Kidney Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Solid Tumors 1Adenocarcinoma of Lung 1ACTH-Secreting Pituitary Adenoma 1

Interventions

pembrolizumab 37Gemcitabine 29Nivolumab 20Cisplatin 19atezolizumab 15avelumab 14Docetaxel 13enfortumab vedotin 10Carboplatin 10durvalumab 9Magnetic Resonance Spectroscopy 9Ipilimumab 8Paclitaxel 7Pemetrexed 6toripalimab 5cabozantinib 5Fluorodeoxyglucose F18 5sacituzumab govitecan 4cabazitaxel 4Taxes 4vinflunine 3tremelimumab 3pemigatinib 3X-Rays 3Standard of Care 3Specimen Handling 3Radiotherapy 3Mitomycin 3Immunotherapy 3Immunoglobulin G 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Transitional Cell × Biomarkers × Clear all
NCT04770974 2022-05-09

Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic

University of Florence

Unknown
200 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡